• Korea Chemical Bank
  • Use of chemicals
Status for use
Procedure for use
Compound use forms
Types of libraries provided
Rights Regulations for
results of Use
Accomplishments

System for entrustment and registration of research results

Go
Accomplishments
Accomplishments
Biological Activity tests
  • Providing support to Pharmaceutical Industries, universities, and research institutes for 80-100 projects every year (Accumulated number of projects thus supported: 600)
  • Providing 200,000-400,000 compounds every year (Accumulated number of compounds thus provided: 4.5 million types)
Cases of state-led projects
  • Small-sized Pharmaceuticals’ New Drug Development Projects; 21st Century Frontier Program
  • MOE’s R&D projects; pan-government projects for development of new drugs; projects for development of disease-focused new drugs
Cases related to new drug candidates
  • Development candidate for treatment of TAZ-related osteoporosis – Licensing to a domestic Pharmaceutical Industries (Shinpoong Pharmaceuticals)
  • Development candidate for treatment of obesity/diabetes (DGATI) – Licensing to a domestic Pharmaceutical Industries (Handok Pharmaceuticals)
  • Development of candidate for treatment of diabetes (DPP-4) – Licensing to a foreign Pharmaceutical Industries (Kainos Med.)
  • Development of candidate for treatment of schizophrenia – Licensing to a domestic Pharmaceutical Industries (Dongwha Pharm)
  • Development candidate for treatment of macular degeneration - Licensing to a domestic Pharmaceutical Industries (Hanlim Pharmaceuticals)
  • Development candidate for treatment of eye diseases – Licensing to a domestic Pharmaceutical Industries (Dongbu Farm Hannong)
  • Development candidate for treatment of AIDS – Licensing to a foreign Pharmaceutical Industries (Gilead)
  • Development candidate for treatment of for treatment of osteoporosis – Licensing to a domestic Pharmaceutical Industries (Oscotec)
  • International joint research with a multinational Pharmaceutical Industries (Eli Lilly) concerning new anti-cancer target exploration
  • Development of fat cell/blood vessel-selective fluorescent indictor
  • Development of a stem cell differentiation promoter
  • Discovery of development candidate for treatment of viral diseases – Licensing to a    multinational pharmaceutical company (2014)
  • Discovery of development candidate for treatment of glaucoma – Licensed to a   domestic Pharmaceutical Industries (Kukje Pharmaceuticals) (2013)
  • Discovery of development candidate for treatment of obesity/diabetes (DGATI) –   Licensed to a domestic Pharmaceutical Industries , Handok Pharmaceuticals (2012)
  • Discovery of development candidate for treatment of AIDS – Licensed to an   nternational Pharmaceutical Industries , Kainos Med (2012)
  • Discovery of development candidate for treatment of osteoporosis (TAZ) – Licensed    to a domestic Pharmaceutical Industries , Shinpoong Pharmaceuticals (2011)
  • Discovery of development candidate for treatment of macular degeneration -   Licensed to a domestic Pharmaceutical Industries , Hanlim Pharmaceuticals (2011)
  • International joint research (new anti-cancer target exploration) – Earning royalties   from Eli Lilly (2010)
Cases of exploration of new drug candidates

Development candidate for treatment of osteoporosis (TAZ)

  • Exploration of initial active compounds from HTS of KCB-stored compounds
  • Development to a candidate substance for treatment of osteoporosis (First-in-Class)
  • Technological transfer to a domestic pharmaceutical
TAZ-골다공증 치료제 후보물질 개발
A case of biological probe development

Development of a lipid-selective fluorescent compound

  • Exploration by HTS of KCB-stored compounds
  • Use in the development of a drug for treatment of obesity, using Zebrafish
  • Licensed out to a domestic pharmaceutical
지질 선택적 형광물질 개발